Related topics: Emerging targets, Drug discovery
Swiss pharma Novartis has got the thumbs up from the EU for its once-yearly treatment for postmenopausal osteoporosis.
Copyright - Unless otherwise stated all contents of this web site are © 2000/2010 - Decision News Media SAS - All Rights Reserved - For permission to reproduce any contents of this web site, please email our Syndication department: Administration & Finance - Full details for the use of materials on this site can be found in the Terms & Conditions